Abstract:Objective: To understand the current status of diagnosis and treatment of chronic lymphocytic leukemia (CLL) /small lymphocytic lymphoma (SLL) among hematologists, oncologists, and lymphoma physicians from hospitals of different levels in China. Methods: This multicenter questionnaire survey was conducted from March 2021 to July 2021 and included 1,000 eligible physicians. A combination of face-to-face interviews and online questionnaire surveys was used. A standardized questionnaire regarding the composition of patients treated for CLL/SLL, disease diagnosis and prognosis evaluation, concomitant diseases, organ function evaluation, treatment selection, and Bruton tyrosine kinase (BTK) inhibitor was used. Results: ①The interviewed physicians stated that the proportion of male patients treated for CLL/SLL is higher than that of females, and the age is mainly concentrated in 61-70 years old. ②Most of the interviewed physicians conducted tests, such as bone marrow biopsies and immunohistochemistry, for patient diagnosis, in addition to the blood test. ③Only 13.7% of the interviewed physicians fully grasped the initial treatment indications recommended by the existing guidelines. ④In terms of cognition of high-risk prognostic factors, physicians' knowledge of unmutated immunoglobulin heavy-chain variable and 11q- is far inferior to that of TP53 mutation and complex karyotype, which are two high-risk prognostic factors, and only 17.1% of the interviewed physicians fully mastered CLL International Prognostic Index scoring system. ⑤Among the first-line treatment strategy, BTK inhibitors are used for different types of patients, and physicians have formed a certain understanding that BTK inhibitors should be preferentially used in patients with high-risk factors and elderly patients, but the actual use of BTK inhibitors in different types of patients is not high (31.6%-46.0%). ⑥BTK inhibitors at a reduced dose in actual clinical treatment were used by 69.0% of the physicians, and 66.8% of the physicians had interrupted the BTK inhibitor for >12 days in actual clinical treatment. The use of BTK inhibitors is reduced or interrupted mainly because of adverse reactions, such as atrial fibrillation, severe bone marrow suppression, hemorrhage, and pulmonary infection, as well as patients' payment capacity and effective disease progression control. ⑦Some differences were found in the perceptions and behaviors of hematologists and oncologists regarding the prognostic assessment of CLL/SLL, the choice of treatment options, the clinical use of BTK inhibitors, etc. Conclusion: At present, a gap remains between the diagnosis and treatment of CLL/SLL among Chinese physicians compared with the recommendations in the guidelines regarding the diagnostic criteria, treatment indications, prognosis assessment, accompanying disease assessment, treatment strategy selection, and rational BTK inhibitor use, especially the proportion of dose reduction or BTK inhibitor discontinuation due to high adverse events.

Comments on Chinese Guidelines for Diagnosis and Treatment of Malignant Lymphoma 2018 (english Version).

Implementation Of Clinical Practice Guidelines For Newly Diagnosed Gbm Patients In China.

Comments on Chinese Guidelines for Diagnosis and Treatment of Gastric Cancer 2018 (english Edition)

The Illness Experiences of Chinese Patients Living with Lymphoma: A Qualitative Study.

Chinese Society of Clinical Oncology (CSCO) Diagnosis and Treatment Guidelines for Malignant Lymphoma 2021 (english Version)

Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition).

Comments on National Guidelines for Diagnosis and Treatment of Melanoma 2022 in China（English Version）

Management Guidelines for Primary Lung Cancer 2018: Chinese Standards in Clinical Practice

China Anti-Cancer Association (CACA) guidelines for holistic integrative management of lymphoma (version 2022)

The interpretation of the Chinese Society of Clinical Oncology clinical guidelines for the diagnosis and treatment of diffuse large B-cell lymphoma

Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition)

Comments on Chinese guidelines for diagnosis and treatment of gastric cancer 2018 (English edition).

Guidelines for the Diagnosis and Treatment of Pancreatic Cancer in China (2021)

Chinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition).

Comments on National Guidelines for Diagnosis and Treatment of Pancreatic Cancer 2022 in China (english Version)

Guidelines of Chinese Society of Clinical Oncology (CSCO) on Diagnosis and Treatment of Breast Cancer (2020 version)

TREATMENT STRATEGIES AND PROGNOSTIC FACTORS OF PRIMARY GASTRIC DIFFUSE LARGE B CELL LYMPHOMA: A RETROSPECTIVE STUDY OF 303 CASES FROM CHINA LYMPHOMA PATIENT REGISTRY

National Guidelines for Diagnosis and Treatment of Colorectal Cancer 2020 in China (english Version)

[Chinese Guidelines on the Diagnosis and Treatment of Primary Lung Cancer (2011 Version)].

Guidelines for Lung Cancer in 2015: Consensus and Controversy

[Current Status of Diagnosis and Treatment of Chronic Lymphocytic Leukemia in China: A National Multicenter Survey Research].